Navigation Links
Hungarian Cancer Formula Producer Questions U.S. Introduction of AveUltra
Date:11/17/2009

BUDAPEST, Hungary, Nov. 17 /PRNewswire/ -- Hungarian drug producer Biropharma and patent holders of its main product Avemar dispute the connection American BioSciences Inc. and its partner Mate Hidvegi are making between their recently introduced product AveUltra and Avemar, a dietary supplement being used in cancer treatment internationally for 11 years.

"AveUltra and Avemar are two different sets of compounds hence the qualities of Avemar can be attributed exclusively to Avemar, therefore all references of AveUltra to Avemar is scientifically unfounded, deceptive and abundantly unethical," Avemar's co-inventors state on Avemar's website (www.avemar.com).

Avemar is a wheat germ extract formula under patent protection designed to treat cancer patients. It is produced by Biropharma based on a definite-term contract with the holders of its patent. The product is distributed under the brand 'Ave' in the U.S.

Hidvegi, one of the patent holders, has teamed up with American BioSciences to start the U.S.-based production of AveUltra, a dietary supplement also based on wheat germ extract, but different from Avemar. According to their claims, AveUltra is developed from Avemar, however, no scientific or otherwise experimental data supports this assertion.

Several clinical studies investigated the various benefits associated with Avemar treatment and the results were published in prestigious peer reviewed medical journals. These publications cannot be used to support the claims of AveUltra.

The producers of AveUltra planned to announce the start of U.S.-based manufacturing of AveUltra at the Society of Integrative Oncology's 6th International Conference at the New York Academy of Medicine on Nov. 12-13.

Avemar's Hungarian producer Biropharma, three co-inventors and a patent holder of Avemar are disputing the steps and behavior of American
'/>"/>

SOURCE Biropharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
2. Biomodels Scientists Report Development of a Novel Model for Cancer Treatment-Related Fatigue
3. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
4. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
5. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
6. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
7. Reportlinker Adds Cancer Vaccines: Measuring Market Potential
8. Texas State University Prepares for Phase 2 Research on the Potential New Cancer and HIV Fighting ALKA-V6 Compound
9. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
10. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
11. Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... for advanced fluid applications and designed for continuous operation up to 1500 bar. ... sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer ...
(Date:7/29/2015)... 2015 Sanofi, un leader ... résultats pour le premier semestre 2015. Le Directeur ... Visionner l,interview vidéo et lire la ... Au sommaire de l,interview :  ... croissance - Diabète - ...
(Date:7/29/2015)... , July 29, 2015 US-Australian drug ... ) today confirmed it is committed to progressing its ... soon as practicable and to ensure the Company delivers ... Executive Officer, Iain Ross , said the Company ... the lead pre-clinical programs, discovery programs and academic partnerships ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... Mass. Researchers at the Harvard School of ... and theoretically that the surface plasmon resonances of ... considerably narrower spectral widths than those of isolated ... significantly more intense in a periodic array, the ...
... can reveal critical evidence, as well as an identity, ... Purdue University that detects trace amounts of explosives, drugs ... The new technology also can distinguish between overlapping fingerprints ... current optical forensic methods. , A team led by ...
... Technology (NIST) have developed a radical new method of focusing ... one nanometer (one billionth of a meter).* Because of the ... range of ions tailored to the task at handit is ... smaller features on semiconductors than now are possible and for ...
Cached Biology Technology:Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths 2Fingerprints provide clues to more than just identity 2Cold atoms could replace hot gallium in focused ion beams 2
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
(Date:7/31/2015)... SHENZHEN, China , 31. Juli 2015 Die ... ) wird von BGI veranstaltet und findet vom ... Shenzhen, China , statt. ... Jubiläum. Seit ihrem Start 2006 ist die ICG ... Bereich „omik" geworden. Sie ist eines der dynamischsten, ...
(Date:7/31/2015)... 31, 2015 The 10 th International Conference ... BGI from October 22-25, 2015, in Shenzhen , ... is celebrating its 10 th anniversary this year. Since its ... most influential annual meetings in the ,omics, fields, and is ... ICG-10 focuses on recent breakthroughs and advances ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... Thinking about adopting a perky little puppy as a friend for ... cats and dogs? Think again. New research at Tel Aviv ... a new recipe for success. According to the study, if the ... when still young (less than 6 months for kittens, a year ...
... Department of Energy Joint Genome Institute (DOE JGI) ... Genomes (IMG) data management system, updated the content ... system, and has launched its educational companion site, ... microbial genomes from Version 29 release of the ...
... (ACCP) has awarded John van den ... Pharmacology at Children,s National Medical Center, its annual ... a neonatologist by training, receives this award for ... pharmacology," according to the ACCP. The Distinguished ...
Cached Biology News:The truth about cats and dogs 2DOE JGI extends the capabilities of the Integrated Microbial Genome System 2DOE JGI extends the capabilities of the Integrated Microbial Genome System 3
Mouse monoclonal antibody raised against a partial recombinant ALPK3. NCBI Entrez Gene ID = ALPK3...
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A...
... Lines ,High Quality, Functionally-Validated, Ion Channel Cell ... for having a critical role in nerve ... key function in pain, CNS and the ... been investigated in therapeutic areas, such as ...
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
Biology Products: